[go: up one dir, main page]

PT97101A - Processo para a preparacao de lipossomas heterovesiculares - Google Patents

Processo para a preparacao de lipossomas heterovesiculares

Info

Publication number
PT97101A
PT97101A PT97101A PT9710191A PT97101A PT 97101 A PT97101 A PT 97101A PT 97101 A PT97101 A PT 97101A PT 9710191 A PT9710191 A PT 9710191A PT 97101 A PT97101 A PT 97101A
Authority
PT
Portugal
Prior art keywords
emulsion
liposomes
preparation
vial
composition
Prior art date
Application number
PT97101A
Other languages
English (en)
Other versions
PT97101B (pt
Inventor
Sinil Kim
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of PT97101A publication Critical patent/PT97101A/pt
Publication of PT97101B publication Critical patent/PT97101B/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Saccharide Compounds (AREA)
PT97101A 1990-03-21 1991-03-21 Processo para a preparacao de lipossomas heterovesiculares PT97101B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49684690A 1990-03-21 1990-03-21

Publications (2)

Publication Number Publication Date
PT97101A true PT97101A (pt) 1991-11-29
PT97101B PT97101B (pt) 1998-08-31

Family

ID=23974416

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97101A PT97101B (pt) 1990-03-21 1991-03-21 Processo para a preparacao de lipossomas heterovesiculares

Country Status (20)

Country Link
EP (1) EP0524968B1 (pt)
JP (1) JP3461000B2 (pt)
KR (1) KR100203223B1 (pt)
CN (1) CN1053101C (pt)
AT (1) ATE123412T1 (pt)
AU (1) AU655177B2 (pt)
CA (1) CA2078666C (pt)
DE (1) DE69110281T2 (pt)
DK (1) DK0524968T3 (pt)
ES (1) ES2073164T3 (pt)
FI (1) FI104464B (pt)
IE (1) IE62772B1 (pt)
IL (1) IL97615A (pt)
NO (1) NO304576B1 (pt)
NZ (1) NZ237464A (pt)
PT (1) PT97101B (pt)
RU (1) RU2120795C1 (pt)
SA (1) SA93130496B1 (pt)
WO (1) WO1991014445A1 (pt)
ZA (1) ZA911974B (pt)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3278273B2 (ja) * 1993-12-17 2002-04-30 キヤノン株式会社 薬剤徐放性カプセル
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
PT948538E (pt) 1996-12-13 2008-08-05 Novartis Vaccines & Diagnostic Análise e separação de proteínas do factor de crescimento derivado de plaquetas
US5985214A (en) 1997-05-16 1999-11-16 Aurora Biosciences Corporation Systems and methods for rapidly identifying useful chemicals in liquid samples
PT1014946E (pt) 1997-09-18 2010-07-06 Pacira Pharmaceuticals Inc COMPOSIÎES ANESTéSICAS LIPOSSOMAIS DE LIBERTAÆO SUSTENTADA
EP1900818A3 (en) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
ATE554748T1 (de) 1997-11-14 2012-05-15 Pacira Pharmaceuticals Inc Herstellung von multivesikulären liposomen
SG152917A1 (en) 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
EP2261350A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
WO2000022130A2 (en) 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
DE69939599D1 (de) 1998-12-16 2008-10-30 Novartis Vaccines & Diagnostic MENSCHLICHE CYCLIN-ABHÄNGIGE KINASE (hPNQALRE)
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7368261B1 (en) 1999-04-30 2008-05-06 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP1801219B1 (en) 1999-10-29 2015-10-14 GlaxoSmithKline Biologicals S.A. Neisserial antigenic peptides
WO2001036640A2 (en) 1999-11-18 2001-05-25 Chiron Corporation Human fgf-21 gene and gene expression products
ATE476988T1 (de) 2000-01-17 2010-08-15 Novartis Vaccines & Diagnostic Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP1370684B1 (en) 2000-06-15 2008-05-28 Novartis Vaccines and Diagnostics, Inc. Polynucleotides related to colon cancer
ES2330083T3 (es) 2000-10-27 2009-12-04 Novartis Vaccines And Diagnostics S.R.L. Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
AU2002227365A1 (en) 2000-12-07 2002-06-18 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
US7309783B2 (en) 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
WO2002094871A1 (en) 2001-05-24 2002-11-28 Human Dna Technology Inc Novel keratinocyte growth factor-2 analogue in hair follicle
CN100398551C (zh) 2001-11-09 2008-07-02 乔治敦大学 新的血管内皮细胞生长抑制剂同种型
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
EP1472375B1 (en) 2002-01-08 2009-04-01 Novartis Vaccines and Diagnostics, Inc. Gene products differentially expressed in cancerous breast cells and their methods of use
WO2003080808A2 (en) 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
RU2338555C2 (ru) 2002-10-08 2008-11-20 Ринат Ньюросайенс Корп. Способы лечения послеоперационной боли введением антагониста фактора роста нервов и композиции, содержащие фактор роста нервов
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
RU2239416C2 (ru) * 2002-12-15 2004-11-10 Ставропольский научно-исследовательский противочумный институт Способ лечения бруцеллеза
RU2234311C1 (ru) * 2002-12-15 2004-08-20 Ставропольский научно-исследовательский противочумный институт Способ лечения бруцеллеза
ES2697876T3 (es) 2002-12-24 2019-01-29 Rinat Neuroscience Corp Anticuerpos anti-NGF y procedimientos de uso de los mismos
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070149449A1 (en) 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
AU2004213044A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ES2481167T3 (es) 2003-08-22 2014-07-29 Dupont Nutrition Biosciences Aps Composición que comprende una bacteriocina y un extracto de una planta de la familia Labiatae
RU2359662C2 (ru) * 2003-08-22 2009-06-27 Даниско А/С Микрокапсулы
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
US7968690B2 (en) 2003-12-23 2011-06-28 Rinat Neuroscience Corp. Agonist anti-trkC antibodies and methods using same
EP1736541B1 (en) 2004-03-29 2013-01-23 Galpharma Co., Ltd. Novel modified galectin 9 protein and use thereof
ES2665758T3 (es) 2004-04-07 2018-04-27 Rinat Neuroscience Corp. Procedimientos de tratamiento del dolor de cáncer de hueso mediante administración de un anticuerpo antagonista del factor de crecimiento neuronal
ES2622394T3 (es) 2004-07-09 2017-07-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Formas solubles de la glicoproteína g del virus hendra
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2404750C2 (ru) 2004-11-23 2010-11-27 Адамас Фармасьютикалс, Инк. Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
EP1845968A2 (en) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 尿路病原性菌株由来の抗原
AU2006244297A1 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of CNS disorders
US20090214536A1 (en) 2005-04-07 2009-08-27 Guoying Yu CACNA1E in Cancer Diagnosis, Detection and Treatment
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US7462698B2 (en) 2005-07-22 2008-12-09 Y's Therapeutics Co., Ltd. Anti-CD26 antibodies and methods of use thereof
SI2380592T1 (en) 2005-11-14 2018-06-29 Teva Pharmaceuticals International Gmbh The antibody to the calcitonin-related peptide antagonist
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
RU2330664C2 (ru) * 2006-04-26 2008-08-10 Александр Иванович Арчаков Лекарственный препарат и способ лечения ревматических заболеваний
EP2044120B1 (en) 2006-06-07 2019-01-30 BioAlliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
EP2134365B1 (en) 2007-03-21 2019-03-13 Effat Emamian Compositions and methods for inhibiting tumor cell growth
US20100261640A1 (en) 2007-04-10 2010-10-14 Branco Luis M Soluble and membrane anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN102216329A (zh) 2007-12-17 2011-10-12 辉瑞有限公司 间质性膀胱炎的治疗
TWI439545B (zh) 2007-12-18 2014-06-01 Bioalliance Cv 辨別癌症細胞表現之cea與cd-43上含醣表位的抗體與其應用方法
RU2367443C1 (ru) * 2008-02-28 2009-09-20 Общество с ограниченной ответственностью "Битеп" Средство на основе природных фосфолипидов
EP2274437B1 (en) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9拮抗劑類
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
RU2011140508A (ru) 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
CA3154626A1 (en) 2009-04-14 2010-10-21 Glaxosmithkline Biologicals S.A. Compositions for immunising against staphylococcus aureus
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
PT2464658E (pt) 2009-07-16 2015-01-14 Novartis Ag Imunogénios de escherichia coli desintoxicados
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP3132793A1 (en) 2009-12-02 2017-02-22 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
CN105218674A (zh) 2010-03-11 2016-01-06 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US9770414B2 (en) * 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
SG11201401699WA (en) 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
WO2013093707A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
EP2866829B1 (en) 2012-07-02 2017-12-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Paramyxovirus and methods of use
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
SG11201503245PA (en) 2012-11-09 2015-05-28 Pfizer Platelet-derived growth factor b specific antibodies and compositions and uses thereof
IL292121B2 (en) 2013-03-15 2024-02-01 Takeda Pharmaceuticals Co Anti-plasma kallikrein antibodies
SG11201508264UA (en) 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
MY190252A (en) 2013-08-02 2022-04-08 Pfizer Anti-cxcr4 antibodies and antibody-drug conjugates
CA2929784C (en) 2013-11-13 2019-11-26 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
FI3119431T3 (fi) 2014-03-21 2024-03-20 Teva Pharmaceuticals Int Gmbh Kalsitoniinigeeniin liittyvää peptidiä vastaan suunnattuja antagonisti-vasta-aineita ja menetelmiä niiden käyttämiseksi
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
NZ771568A (en) 2015-01-02 2024-11-29 Takeda Pharmaceuticals Co Bispecific antibodies against plasma kallikrein and factor xii
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
AU2016297018B9 (en) 2015-07-21 2022-12-01 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor XIIa
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
CN107922506B (zh) 2015-08-19 2021-11-09 辉瑞公司 组织因子途径抑制剂抗体及其用途
SMT202500263T1 (it) 2015-09-15 2025-09-12 Scholar Rock Inc Anticorpi anti-pro-miostatina/miostatina latente e loro usi
JP6661319B2 (ja) * 2015-09-28 2020-03-11 小林製薬株式会社 リポソーム
CA2946113A1 (en) 2015-10-23 2017-04-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技(上海)有限公司 抗pd-1抗体及其治疗用途
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
DK3405490T3 (da) 2016-01-21 2022-01-10 Pfizer Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
KR102069680B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
MX2019010458A (es) 2017-03-03 2020-01-20 Rinat Neuroscience Corp Anticuerpos anti-gitr y metodos de uso de los mismos.
EP3596206A1 (en) 2017-03-16 2020-01-22 Pfizer Inc Tyrosine prototrophy
WO2018191548A2 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
TWI790120B (zh) 2017-06-02 2023-01-11 美商輝瑞大藥廠 對flt3具特異性之抗體及其用途
CA3066004A1 (en) 2017-06-13 2018-12-20 Bostongene Corporation Systems and methods for identifying cancer treatments from normalized biomarker scores
BR112020000679A2 (pt) 2017-07-13 2020-07-14 Massachusetts Institute Of Technology visando o complexo hdac2-sp3 para potencializar a função sináptica
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
KR20210027230A (ko) 2017-10-04 2021-03-10 옵코 파마슈티칼스, 엘엘씨 암의 개인 맞춤형 치료에 관한 물품 및 방법
AU2018355588C1 (en) 2017-10-27 2023-04-27 New York University Anti-Galectin-9 antibodies and uses thereof
CN111936519A (zh) 2018-02-01 2020-11-13 辉瑞公司 对cd70具有特异性的抗体及其用途
EP3746483A1 (en) 2018-02-01 2020-12-09 Pfizer Inc Chimeric antigen receptors targeting cd70
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
JP2021514656A (ja) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. Il−6抗体ならびにその融合構築物およびコンジュゲート
EP3797121B1 (en) 2018-05-23 2024-06-19 Pfizer Inc. Antibodies specific for cd3 and uses thereof
TWI803637B (zh) 2018-05-23 2023-06-01 美商輝瑞大藥廠 特異性針對gucy2c之抗體及其用途
WO2020078270A1 (en) 2018-10-15 2020-04-23 Elixiron Immunotherapeutics (hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof
WO2020132190A1 (en) 2018-12-21 2020-06-25 Multitude Inc. Antibodies specific to muc18
WO2020154548A2 (en) 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
US12205675B2 (en) 2019-07-03 2025-01-21 Bostongene Corporation Techniques for bias correction in sequence data
CA3153932A1 (en) 2019-10-07 2021-04-15 Jonathan Kipnis Modulating lymphatic vessels in neurological disease
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4041773A1 (en) 2019-10-11 2022-08-17 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
US20230235007A1 (en) 2020-06-15 2023-07-27 Ming-Che Shih Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
IL299939A (en) 2020-07-17 2023-03-01 Pfizer Therapeutic antibodies and their uses
EP4189093A1 (en) 2020-07-30 2023-06-07 Pfizer Inc. Cells having gene duplications and uses thereof
JP2023540098A (ja) 2020-09-03 2023-09-21 チェン アーヴィン エス.ワイ. 可溶性アルカリホスファターゼ構築物及び可溶性アルカリホスファターゼ構築物をコードするポリヌクレオチドを含む発現ベクター
US20240029829A1 (en) 2020-12-04 2024-01-25 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
JP2024517745A (ja) 2021-04-29 2024-04-23 ボストンジーン コーポレイション 複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法
WO2023012627A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
GB2627096A (en) 2021-10-14 2024-08-14 Pacira Pharmaceuticals Inc Bupivacaine multivesicular liposome formulations and uses thereof
WO2023147177A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
KR20240139082A (ko) 2022-02-02 2024-09-20 화이자 인코포레이티드 시스테인 프로토트로피
EP4555107A1 (en) 2022-07-15 2025-05-21 BostonGene Corporation Techniques for detecting homologous recombination deficiency (hrd)
CN115957213A (zh) * 2022-12-30 2023-04-14 青岛市胶州中心医院 一种抗感染甲硝唑制剂及其制备方法
WO2025096811A1 (en) 2023-10-31 2025-05-08 Bostongene Corporation Machine learning technique for identifying ici responders and non-responders
WO2025157994A1 (en) 2024-01-25 2025-07-31 Intervet International B.V. Vaccine against ruminant respiratory disease
US20250253011A1 (en) 2024-02-02 2025-08-07 Seven Bridges Genomics Inc. Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference
US12251468B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12156940B1 (en) 2024-05-20 2024-12-03 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
EP0199362A3 (en) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology System and apparatus for delayed and pulsed release of biologically active substances
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes

Also Published As

Publication number Publication date
AU655177B2 (en) 1994-12-08
AU7580691A (en) 1991-10-21
CA2078666C (en) 2001-10-02
WO1991014445A1 (en) 1991-10-03
NO304576B1 (no) 1999-01-18
EP0524968A4 (en) 1993-03-24
DE69110281D1 (de) 1995-07-13
RU2120795C1 (ru) 1998-10-27
KR100203223B1 (ko) 1999-06-15
NO923624L (no) 1992-09-17
NO923624D0 (no) 1992-09-17
ATE123412T1 (de) 1995-06-15
IL97615A0 (en) 1992-06-21
CN1053101C (zh) 2000-06-07
DK0524968T3 (da) 1995-07-31
PT97101B (pt) 1998-08-31
FI924193A0 (fi) 1992-09-18
JP3461000B2 (ja) 2003-10-27
ZA911974B (en) 1994-08-22
IE910911A1 (en) 1991-09-25
IE62772B1 (en) 1995-02-22
SA93130496B1 (ar) 2004-08-14
IL97615A (en) 1995-06-29
DE69110281T2 (de) 1995-11-09
CA2078666A1 (en) 1991-09-22
ES2073164T3 (es) 1995-08-01
JPH05507680A (ja) 1993-11-04
CN1055663A (zh) 1991-10-30
EP0524968A1 (en) 1993-02-03
FI104464B (fi) 2000-02-15
FI924193L (fi) 1992-09-18
EP0524968B1 (en) 1995-06-07
NZ237464A (en) 1995-02-24

Similar Documents

Publication Publication Date Title
PT97101A (pt) Processo para a preparacao de lipossomas heterovesiculares
MX9305444A (es) Derivados de rodanina como agentes hipoglucemicos y para el tratamiento de la enfermedad de alzheimer, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
ATE82495T1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
DK0478686T3 (da) Flour- og phosphorholdige amphiphile molekyler med overfladeaktive egenskaber
DE3577851D1 (de) Inositoltriphosphat, verfahren zu seiner herstellung und dieses enthaltende zubereitung.
MX9203667A (es) Sales de bis-dimetoximetil (trimetoxibencil)quinolino, su preparacion y composicines farmaceuticas que las contienen.
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
KR900701174A (ko) 인지질-함유 조성물, 이의 제조방법 및 이의 약제학적 물질용 부형제로서의 용도
PT76502A (en) Process for the preparation of n-glycosylated carboxamide derivatives with s stimulating effect of the body's inherent defences and their application for the preparation of pharmaceutical compositions having a stimulating effect of body's inherent defences
ES2085920T3 (es) Liposomas dirigidos y metodos de acoplamiento liposoma-proteina.
MX24839A (es) 3-arilcarbonil-1-aminoalquilo-1h-indoles, proceso para su preparacion y composicion farmaceutica quelos contiene.
PT79648B (de) Verfahren zur herstellung von pharmazeutischen zubereitungen mit speziellen 1,2-diacyl-glycero-3-phosphocholinen zur behandlung von erkrankungen im magen-darm-bereich
DE69033745D1 (de) Oberflächenaktive zusammensetzungen und verfahren
ES2042437T1 (es) Procedimiento de preparacion de una lipoproteina modificaa por incorporacion de una substancia activa lipofila.
DE3166084D1 (en) Tricyclic cytosine derivatives for use in pharmaceutical preparations and process for their preparation
DE2961609D1 (en) Sila-substituted 1,4-dihydropyridine derivatives, processes for their preparation, pharmaceutical compositions and process for their preparation
DE59505146D1 (de) Liposomen enthaltend darin verkapselte proteine, verfahren zu ihrer herstellung sowie diese liposomen enthaltende pharmazeutische und kosmetische zubereitungen
HU900753D0 (en) Process for preparation of phenylhydrazones and for pharmaceutical compositions containing them
ATE3552T1 (de) Verfahren zur herstellung von phosphono-hydroxy- essigsaeure und salzen derselben sowie diese enthaltende autivirale mittel.
ATE40793T1 (de) Pharmazeutisches praeparat zur therapeutischen behandlung von rheumatischen erkrankungen.
ES2062891T3 (es) Compuestos de 1,2,3,4-oxatriazol-5-imina 3-sustituidos, un proceso para la preparacion de los mismos y un preparado farmaceutico que contiene tales compuestos.
SE8503447L (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
PT98063A (pt) Processo de preparacao de compostos de 4-amino-imidazo-quinoxalina e de 5-amino-imidazo-quinazolina e de composicoes farmaceuticas
ATE135T1 (de) 2-substituierte-3-heterocycloindole, verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19910724

FG3A Patent granted, date of granting

Effective date: 19980505

PD3A Change of proprietorship

Owner name: SKYEPHARMA INC.

Effective date: 19991115

TE3A Change of address (patent)

Owner name: SKYEPHARMA INC.

Effective date: 19991115

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20091105